Evidence map›Paper›PMID 33547557›Full record

ArticleHepatology international2021

One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment.

Tai-Chung Tseng, Jonggi Choi, Mindie H Nguyen, Cheng-Yuan Peng, Spyros Siakavellas, George Papatheodoridis, Chia-Chi Wang, Young-Suk Lim, Hsueh-Chou Lai, Huy N Trinh and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hepatology international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Tai-Chung TsengDivision of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, 1 Chang-Te St, Taipei, 10002, Taiwan.
Jonggi ChoiDepartment of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Mindie H NguyenDivision of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA, USA.
Cheng-Yuan PengSchool of Medicine, China Medical University, Taizhong, Taiwan.
Spyros SiakavellasDepartment of Gastroenterology, Medical School of National and Kapodistrian University of Athens, General Hospital of Athens "Laiko", Athens, Greece.
George PapatheodoridisDepartment of Gastroenterology, Medical School of National and Kapodistrian University of Athens, General Hospital of Athens "Laiko", Athens, Greece.
Chia-Chi WangDivision of Gastroenterology, Department of Internal Medicine, Taipei Tzuchi Hospital, The Buddhist Tzuchi Medical Foundation, New Taipei City, Taiwan.
Young-Suk LimDepartment of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Hsueh-Chou LaiSchool of Medicine, China Medical University, Taizhong, Taiwan.
Huy N TrinhSan Jose Gastroenterology, San Jose, CA, USA.
Christopher WongWong Clinics, San Francisco, CA, USA.
Clifford WongWong Clinics, San Francisco, CA, USA.
Jian ZhangChinese Hospital, San Francisco, CA, USA.
Jiayi LiGastroenterology, Palo Alto Medical Foundation, Mountain View, CA, USA.
Jia-Horng KaoDivision of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, 1 Chang-Te St, Taipei, 10002, Taiwan. kaojh@ntu.edu.tw.ORCID http://orcid.org/0000-0002-2442-7952

Funding

Ministry of Science and Technology, Taiwan MOST 106-2314-B-002 -136National Health Research Institutes NHRI-EX108-10807BCNational Taiwan University Hospital 107-N4041National Taiwan University Hospital 108-N4157National Taiwan University Hospital 109-N4644
6 · The paper itself

Abstract

BACKGROUND AND

aimsFibrosis-4 (FIB-4) index is a HCC predictor in chronic hepatitis B (CHB) patients. However, little is known about whether FIB-4 helps identify non-cirrhotic CHB patients with minimal HCC risk after prolonged nucleos(t)ide analogue (NA) therapy.

methodsA total of 1936 ethnically diverse, non-cirrhotic CHB patients were enrolled in this retrospective multi-national study. All patients received prolonged NA treatment, including entecavir and tenofovir disoproxil fumarate. We explored whether FIB-4 cutoff of 1.30, a marker indicative of mild fibrosis severity, could stratify HCC risks in these patients.

resultsA total of 48 patients developed HCC after a mean follow-up of 6.98 years. FIB-4 level at 1 year after treatment (1-year FIB-4) was shown to be associated with HCC development and was superior to pre-treatment FIB-4 value. When patients were stratified by 1-year FIB-4 of 1.30, the high FIB-4 group was at an increased HCC risk compared to the low FIB-4 group, with a hazard ratio of 4.87 (95% confidence interval: 2.48-9.55). Multivariable analysis showed that sex and 1-year FIB-4 were independent predictors, with none of the 314 female patients with low 1-year FIB-4 developing HCC. Finally, 1-year FIB-4 of 1.30 consistently stratified HCC risks in patients with low PAGE-B score, a score composed of baseline age, sex and platelet count, and the annual incidence rate of HCC was 0.11% in those with PAGE-B < 10 + 1-year FIB-4 < 1.30.

conclusionsIn non-cirrhotic CHB patients receiving prolonged NA therapy, 1-year FIB-4 < 1.30 is useful for identifying those with minimal HCC risk by combining with female sex or low PAGE-B score.

Indexed as

Carcinoma, HepatocellularHepatitis B, ChronicLiver CirrhosisLiver NeoplasmsAntiviral AgentsFemaleHumansRetrospective StudiesAntiviral AgentsEntecavirFIB-4HBVHepatocellular carcinomaPAGE-BTenofovir

Identifiers

PMID33547557
PMCPMC7863859

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.